Skip to main content

Table 2 Treatment modalities and outcomes of women with radiogenic angiosarcoma of the breast

From: Radiogenic angiosarcoma of the breast: case report and systematic review of the literature

Author Year Treatment modalities (Initial) Treatment modalities (Recurrence) Chemotherapy (n)/ regimen RXT (n)/ gray Recurrence-Free survival (m) Overall survival (m)
Fodor [4] 2006 MAS (8) S + CHXT (1) 1/DOCE 16 26
Marchal [5] 1999 MAS (4);MAS + CHXT (2); MAS + RXT (2);MAS + S (1) S (1);RXT; CHXT (7) 2/− 3/30;45a 7 15
D’Angelo [6] 2013 MAS (65);S (13)a; CHXT (9) CHXT (23) 23/DOX (9), PAC (3), SORA (3), BRIV (2), IFO (1), DOX + PAC (1), GEM+DOCE (1), SIR (1) 16 36
Strobbe [9] 1998 MAS (20);MAS + S (1) S (7) 13 27
Smith [12] 2014 MAS (6);MAS + RXT (8) RXT (6) 14/45 (2);60 (3);75 (9)   97
West [19] 2005 MAS (2);MAS + RXT (1);MAS + CHXT (1) S (1); CHXT (1) 2/TAX;ADR 2/− 26;6;3;5 26;19;12;6
Rao [20] 2003 MAS (3) S + CHXT (1) 41;3;7 41;12;7
Polgár [21] 2001 MAS (1);NT (1) MAS (1) 36;4 36;4
Vesoulis [22] 2000 MAS + CHXT (1)   1/−
Wijnmaalen [24] 1993 MAS (2);MAS + S (1) S (1) 7;16;30 7;30;34
Otis [27] 1986 S (2) 1/− 2
Armengot-Carbó [29] 2012 MAS (1) 9 9
Fernández [30] 2006 MAS (2) S (1) 8;50 10;50
Colville [33] 2000 S (1) MAS;S;RXT (1) 1/40 8 20
Hogewind [34] 2004 MAS (2) S (1) 4;24 4,24
Williams [35] 2004 MAS (1) 5 5
Deutsch [37] 2003 MAS + S (1) S;RXT (1) 1/− 4 23
Hildebrandt [41] 2001 MAS (1) S (1) 16 23
Esler-Brauer [7] 2007 MAS (1) 45 45
Catena [42] 2006 MAS (1) 10 10
Moe [43] 2007 MAS (1) S;CHXT (1) 1/DOX;IFO 2 20
Hodgson [45] 2007 MAS (25)  
Soldić [48] 2009 MAS 16 16
Zucali [53] 1994 S (1);MAS (2); MAS + S (1) S + RXT (1);CHXT (1) 1/− 1/60 96;4;13 96;7;24
Aydogdu [54] 1996 MAS (1) 3
Weber [56] 1995 S (2);RXT + CHXT (1) RXT;CHXT (1) 1/5-FU, DOX 36;24 36;24
Majeski [57] 2000 MAS + S (1) S (1) 26 29
Nakamura [60] 2007 MAS + CHXT (1) 1/PAC 15 15
Billings [64] 2004 MAS (10); S (10)a CHXT (4) 4/− 42
Navarro Cecilia [67] 2015 MAS (1) S (1) 1 7
Uryvaev [68] 2015 MAS (3);MAS + RXT (3) RXT (2);CHXT (3) 3/ADR + IFO (1); DOX + PAC (2) 3/50 (2);16 (1) 43
Gennaro [69] 2010 MAS (9) 5/ADR + IFO
Feigenberg [8] 2002 MAS (3) RXT (3) 3/60 (2);50 (1) 2;1;22 41;60;22
Hui [71] 2012 MAS (1);MAS + RXT (4);MAS + CHXT (3) 3/PAC
Adhikari [72] 2002 S + RXT + CHXT (1) S (1) 1/ADR + CYC 1/50 13 16
Hanasono [74] 2005 S (1) S,CHXT (1) 2 13
Mocerino [75] 2016 MAS (1) S;CHXT;RXT (1) 1/BLEO;DOX 1/60 12 24
Moskaluk [78] 1992 S (1) MAS (1) 24 96
Pooled Analysis MAS (83%); S (13%); CHXT (4%) (adjuvant); RXT (6%) (adjuvant) CHXT (58%); S (33%); RXT (30%)b 15.9 27.4
  1. Abbreviations: 5-FU 5-fluorouracil, ADR adriamycin, BLEO bleomycin, BRIV brivanib, CHXT chemotherapy, CYC cyclophosphamide, DOCE docetaxel, DOX doxoribicin, GEM gemcitabine, IFO ifosfamide, m months, MAID doxorubicin, ifosfamide, dacarbazine, MAS mastectomy, n number, NT no treatment, PAC paclitaxel, RXT radiotherapy, S surgery, SIR sirolimus, SORA sorafenib
  2. aMissing cases not documented
  3. bmultiple therapies possible